Goldman Sachs Group Inc. restated their buy rating on shares of Allergan PLC (NYSE:AGN) in a research note issued to investors on Tuesday morning. They currently have a $300.00 price objective on the stock.
AGN has been the subject of a number of other reports. Credit Suisse Group AG initiated coverage on shares of Allergan PLC in a research report on Monday, July 25th. They issued an outperform rating and a $327.00 price objective for the company. Zacks Investment Research cut shares of Allergan PLC from a buy rating to a hold rating in a research report on Tuesday, July 26th. Vetr cut shares of Allergan PLC from a strong-buy rating to a buy rating and set a $283.05 price objective for the company. in a research report on Monday, August 8th. Leerink Swann set a $294.00 price objective on shares of Allergan PLC and gave the company a buy rating in a research report on Monday, August 8th. Finally, Royal Bank Of Canada decreased their price objective on shares of Allergan PLC from $307.00 to $300.00 and set an outperform rating for the company in a research report on Tuesday, August 9th. Six equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Allergan PLC presently has an average rating of Buy and a consensus target price of $300.64.
Shares of Allergan PLC (NYSE:AGN) opened at 230.31 on Tuesday. The stock’s 50 day moving average price is $242.33 and its 200-day moving average price is $240.70. The firm has a market cap of $91.19 billion, a PE ratio of 21.93 and a beta of 0.81. Allergan PLC has a 52-week low of $195.50 and a 52-week high of $322.68.
Allergan PLC (NYSE:AGN) last announced its quarterly earnings results on Monday, August 8th. The company reported $3.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.34 by $0.01. Allergan PLC had a return on equity of 7.67% and a net margin of 28.06%. The firm earned $3.68 billion during the quarter, compared to the consensus estimate of $4.10 billion. During the same period in the prior year, the firm earned $4.41 EPS. The firm’s quarterly revenue was up 1.0% compared to the same quarter last year. On average, equities research analysts anticipate that Allergan PLC will post $14.00 earnings per share for the current fiscal year.
Several hedge funds and other institutional investors have recently bought and sold shares of AGN. Barnett & Company Inc. acquired a new position in Allergan PLC during the first quarter valued at about $111,000. Ropes Wealth Advisors LLC raised its position in Allergan PLC by 13.2% in the first quarter. Ropes Wealth Advisors LLC now owns 497 shares of the company’s stock valued at $133,000 after buying an additional 58 shares during the period. Livingston Group Asset Management CO operating as Southport Capital Management acquired a new position in Allergan PLC during the second quarter valued at about $125,000. Trust Co. of Vermont raised its position in Allergan PLC by 19.5% in the second quarter. Trust Co. of Vermont now owns 545 shares of the company’s stock valued at $126,000 after buying an additional 89 shares during the period. Finally, Integrated Investment Consultants LLC raised its position in Allergan PLC by 35.2% in the second quarter. Integrated Investment Consultants LLC now owns 592 shares of the company’s stock valued at $137,000 after buying an additional 154 shares during the period. Institutional investors and hedge funds own 85.19% of the company’s stock.
Allergan PLC Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC and related companies with MarketBeat.com's FREE daily email newsletter.